Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul;210(1):54-63.
doi: 10.1097/JU.0000000000003492. Epub 2023 Apr 25.

Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy

Affiliations

Early Detection of Prostate Cancer: AUA/SUO Guideline Part II: Considerations for a Prostate Biopsy

John T Wei et al. J Urol. 2023 Jul.

Abstract

Purpose: The summary presented herein covers recommendations on the early detection of prostate cancer and provides a framework to facilitate clinical decision-making in the implementation of prostate cancer screening, biopsy, and follow-up. This is Part II of a two-part series focusing on initial and repeat biopsies, and biopsy technique. Please refer to Part I for discussion of initial prostate cancer screening recommendations.

Materials and methods: The systematic review utilized to inform this guideline was conducted by an independent methodological consultant. The systematic review was based on searches in Ovid MEDLINE and Embase and Cochrane Database of Systematic Reviews (January 1, 2000-November 21, 2022). Searches were supplemented by reviewing reference lists of relevant articles.

Results: The Early Detection of Prostate Cancer Panel developed evidence- and consensus-based guideline statements to provide guidance in prostate cancer screening, initial and repeat biopsies, and biopsy technique.

Conclusions: The evaluation of prostate cancer risk should be focused on the detection of clinically significant prostate cancer (Grade Group 2 or higher [GG2+]). The use of laboratory biomarkers, prostate MRI, and biopsy techniques described herein may improve detection and safety when a prostate biopsy is deemed necessary following prostate cancer screening.

Keywords: AIP; ASAP; HGPIN; MRI; PI-RADS; PSA; biomarkers; biopsy technique; early detection of prostate cancer; imaging; prostate cancer biopsy; prostate cancer screening; transperineal; transrectal.

PubMed Disclaimer

Figures

FIGURE 2:
FIGURE 2:
ELEVATED RISK EVALUATION
FIGURE 3:
FIGURE 3:
AFTER A NEGATIVE BIOPSY

Similar articles

Cited by

References

    1. Wei JT, Feng Z, Partin AW et al.: Can urinary pca3 supplement psa in the early detection of prostate cancer? Journal of Clinical Oncology 2014; 32: 4066. - PMC - PubMed
    1. Eastham JA, Boorjian SA and Kirkby E: Clinically localized prostate cancer: Aua/astro guideline. J Urol 2022; 208: 505. - PubMed
    1. Kasivisvanathan V, Rannikko AS, Borghi M et al.: Mri-targeted or standard biopsy for prostate-cancer diagnosis. N Engl J Med 2018; 378: 1767. - PMC - PubMed
    1. Drost FH, Osses DF, Nieboer D et al.: Prostate mri, with or without mri-targeted biopsy, and systematic biopsy for detecting prostate cancer. Cochrane Database of Systematic Reviews 2019; 4: CD012663. - PMC - PubMed
    1. Cata E, Andras I, Ferro M et al.: Systematic sampling during mri-us fusion prostate biopsy can overcome errors of targeting-prospective single center experience after 300 cases in first biopsy setting. Translational Andrology & Urology 2020; 9: 2510. - PMC - PubMed

Substances